391 related articles for article (PubMed ID: 2217409)
1. Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.
Keating JP; Zincke H; Hahn RG; Morgan WR
Prog Clin Biol Res; 1990; 353():119-27. PubMed ID: 2217409
[No Abstract] [Full Text] [Related]
2. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
Koch MO; Coussens D
Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
[No Abstract] [Full Text] [Related]
3. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience.
Fair WR; Scher H; Herr H; Morse M; Sogani P; Bosi G; Dershaw D; Reuter V; Curley T
Semin Urol; 1990 Aug; 8(3):190-6. PubMed ID: 2399387
[No Abstract] [Full Text] [Related]
5. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
Klän R; Knispel H; Huland H
Urologe A; 1992 Jul; 31(4):247-50. PubMed ID: 1514213
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant M-VAC chemotherapy and partial cystectomy for treatment of locally invasive transitional cell carcinoma of the bladder.
Simon SD; Srougi M
Prog Clin Biol Res; 1990; 353():169-74. PubMed ID: 2217415
[No Abstract] [Full Text] [Related]
7. Organ conservation in deeply invasive bladder cancer.
Fair WR
Prog Clin Biol Res; 1991; 370():119-26. PubMed ID: 1924440
[No Abstract] [Full Text] [Related]
8. Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Bosl G; Watson RC; Hollander PS
Prog Clin Biol Res; 1988; 260():551-5. PubMed ID: 3283770
[No Abstract] [Full Text] [Related]
9. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
10. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
Hoch V; Noll F; Schreiter F
Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
[TBL] [Abstract][Full Text] [Related]
11. M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
Scher H; Herr H; Sternberg C; Fair W; Bosl G; Morse M; Sogani P; Watson R; Darshaw D; Reuter V
Prog Clin Biol Res; 1990; 353():179-86. PubMed ID: 2217417
[No Abstract] [Full Text] [Related]
12. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
13. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
[No Abstract] [Full Text] [Related]
14. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer.
Takata R; Obara W; Fujioka T
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S41-5. PubMed ID: 20094952
[TBL] [Abstract][Full Text] [Related]
15. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
[TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
Sternberg CN; Yagoda A; Scher HI
Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909
[No Abstract] [Full Text] [Related]
19. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
20. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]